IE
ANAB icon

Israel Englander’s AnaptysBio ANAB Stock Holding History

Israel Englander’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-90,000
Closed -$8.98M – 3718
2018
Q3 		$8.98M Buy
90,000
+15,000
+20% +$1.24M 0.01% 1393
2018
Q2 		$5.33M Buy
+75,000
New +$6.29M 0.01% 1774

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's ANAB Position: Q2 2026 in Review

Israel Englander increased its AnaptysBio (ANAB) stake by 70% in Q2 2026, buying an estimated $20.1M and bringing the position to 807,316 shares worth $54.5M. The position accounts for 0.02% of the portfolio, ranked #845.

Israel Englander first reported a position in ANAB in Q1 2017 and has held it in 36 quarters since. 211 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Israel Englander held 807,316 shares of AnaptysBio worth $54.5M as of Q2 2026.
  • Israel Englander bought 331,744 AnaptysBio shares in Q2 2026, an estimated $20.1M.
  • AnaptysBio made up 0.02% of Israel Englander's portfolio in Q2 2026, its #845 holding.
  • Israel Englander first reported a position in AnaptysBio in Q1 2017 and has held it in 36 quarters since.
  • 211 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.